1. Home
  2. XYF vs NKTX Comparison

XYF vs NKTX Comparison

Compare XYF & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo X Financial each representing six

XYF

X Financial each representing six

N/A

Current Price

$5.51

Market Cap

179.1M

Sector

Finance

ML Signal

N/A

Logo Nkarta Inc.

NKTX

Nkarta Inc.

N/A

Current Price

$1.19

Market Cap

198.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XYF
NKTX
Founded
2014
2015
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.1M
198.2M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
XYF
NKTX
Price
$5.51
$1.19
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $10.80
AVG Volume (30 Days)
71.9K
★ 1.6M
Earning Date
11-27-2026
11-05-2026
Dividend Yield
★ 10.19%
N/A
EPS Growth
N/A
★ 11.88
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.90
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.30
$1.13
52 Week High
$11.75
$3.72

Technical Indicators

Market Signals
Indicator
XYF
NKTX
Relative Strength Index (RSI) 59.17 29.05
Support Level $4.53 N/A
Resistance Level $5.72 $1.86
Average True Range (ATR) 0.30 0.19
MACD 0.08 -0.01
Stochastic Oscillator 75.73 9.52

Price Performance

Historical Comparison
XYF
NKTX

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, guarantee services provided and financing income.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: